Early Life
Philipp Boehringer's story begins with the legacy of Boehringer Ingelheim, a company founded in 1885 by Albert Boehringer in Ingelheim am Rhein, Germany. The company initially focused on producing ingredients for pharmacies, textile merchants, and the food industry. This early focus laid the foundation for the company's later expansion into pharmaceuticals. Philipp is part of the third, fourth, or fifth generation of the Boehringer family involved in the business.
Rise to Success
Boehringer's wealth and influence stem from his ownership stake in Boehringer Ingelheim. The company's success is a result of its commitment to research, development, and manufacturing of new medications, focusing on areas of unmet medical needs for both humans and animals. Key milestones include innovations in respiratory medicine, such as Spiriva for chronic obstructive pulmonary disease (COPD), and its leading position in animal health, providing vaccines and treatments. Boehringer Ingelheim has grown to employ over 54,000 people globally and operates in 130 markets.
Key Business Strategies
Boehringer Ingelheim's strategies include strategic investments in research and development and manufacturing, with a focus on long-term performance and organic growth. They have a strong pipeline of new treatments and have invested heavily in R&D, with approximately EUR 6.2 billion invested in 2024. The company's commitment to innovation has helped it to maintain a strong position in the pharmaceutical industry. The company has also invested heavily in its global infrastructure, including a new facility in Japan and the strengthening of its local production network in the USA.
Philanthropy
Boehringer Ingelheim is involved in various philanthropic initiatives. The company supports the Vienna Research Institute of Molecular Pathology (IMP). Additionally, the company is committed to improving the health of both humans and animals and ensures access to life-changing and life-saving medications.
